New report from FDI World Dental Federation tackles oral health inequalities and outlines strategies to improve oral healthcare over the next ten years
plus
Actualités sur Santè / Médecine
ForaCare Suisse AG releases Rapid COVID-19 Antigen Test / Test Results in 15 Minutes, No Laboratory Processing Required, Highly Accurate & Reliable Results
ST. GALLEN, Switzerland (ots) - ForaCare Suisse AG announced the release of its antigen test, FORA COVID-19 Antigen Rapid Test, that provides fast, accurate and easy-to-interpret test results. The test can be administered by trained professionals and doesn’t rely on laboratory-processing. Approved by Swissmedic, ...
plusRoche teams up with Diabeloop to advance the management of insulin pump therapy
Basel (ots) - - The partnership will create new opportunities to lower the burden for people with diabetes in daily therapy management and to improve therapy outcomes(1). - By partnering with Diabeloop, Roche steps into the field of automated insulin delivery (AID) representing a milestone in Roche's strategy of integrated Personalised Diabetes Management (iPDM). Roche ...
plusHelsana Drug Report: Spitex patients exposed to significant medication risks
Zurich (ots) - In 2019, medication costs in Switzerland totalled approximately CHF 7.6 billion. The front runners remained cancer and immune system drugs, followed by nervous system medications and metabolic preparations. The use of biosimilars (generic preparations) offers significant savings potential that unfortunately remains almost completely unexploited. In an ...
plus- 3
Global leaders welcome the Sanitation and Hygiene Fund as key to increasing investment
plus Study shows dramatic rise in antibiotics prescribed to dental patients in England during COVID-19 lockdown earlier this year
plusFORA® 6 Blood Glucose Monitors Help Diabetic Patients Monitor COVID-19 Risks
plus- 2
The Sanitation and Hygiene Fund to be launched on 17 November
plus Swiss Rockets AG announces the founding of ROCKETVAX for the development of a next-generation SARS-CoV-2 vaccine
plusFDI World Dental Federation says Be Proud of Your Mouth for World Oral Health Day 2021 to 2023
plusThe International Osteoporosis Foundation (IOF)
One broken bone leads to another, warns IOF on World Osteoporosis Day
plusDebiopharm and the Japanese Cancer Association Announce Winners of the 2020 JCA-Mauvernay Award
Lausanne (ots) - For its sixteenth edition, the JCA-Mauvernay Award was awarded to Doctor Hideaki Ogiwara and Doctor Keisuke Kataoka Debiopharm (www.debiopharm.com), a Swiss-based global, biopharmaceutical company, presented the JCA-Mauvernay Award on October 3rd to Dr. Hideaki Ogiwara from the Division of Cancer Therapeutics of the National Cancer Center Research ...
plusDEBIOPHARM LAUNCHES TRILYNX - A LARGE-SCALE PHASE III CLINICAL TRIAL TO FURTHER EVALUATE XEVINAPANT IN THE TREATMENT OF HEAD & NECK CANCER
Lausanne, Switzerland (ots) - First patient dosed in the randomized, placebo-controlled Phase III study of xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) Debiopharm (www.debiopharm.com), a ...
plusFDI World Dental Federation and Smile Train: Children with clefts are at high risk for tooth decay, gum disease and other serious oral health concerns
plusDEBIOPHARM HONORED AS A 2020 SWISS BIOTECH SUCCESS STORY WINNER FOR OUTSTANDING ACHIEVEMENTS OVER 40 YEARS
Lausanne, Switzerland (ots) - Debiopharm, (www.debiopharm.com), a Swiss-based biopharmaceutical company today announced being one of the recipients of the 2020 Swiss Biotech Success Story Award for exceptional achievements in the biotech industry. Every year, the Swiss Biotech Association awards companies or ...
plusBelgian scale-up Oncomfort raises EUR10 million in Series A funding co-led by Debiopharm and Crédit Mutuel Innovation to further develop its Digital SedationTM through Virtual Reality
plusZur Rose and KPT together launch digital medicines assistant Medi+
plusMSD (Merck Sharp & Dohme AG) Switzerland appoints Ans Heirman, Ph.D. as the new Managing Director of MSD Switzerland, effective September 1st, 2020
Un documentplusDEBIOPHARM'S NEW GENERATION RADIONUCLIDE THERAPY ADVANCES INTO CLINICAL RESEARCH IN THE FIGHT AGAINST LUNG CANCER
Lausanne (ots) - First patient dosed in the phase I small cell lung cancer (SCLC) trial with Debio 1124, a molecular-targeted radiotherapy Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced the first patient dosed in the multicenter, single-arm, open-label Phase 1 study ...
plusDEBIOPHARM'S IAP ANTAGONIST SIGNIFICANTLY IMPROVES OVERALL SURVIVAL OF HIGH-RISK HEAD & NECK CANCER PATIENTS
Lausanne, Switzerland (ots) - Promising overall survival outcomes at 3-years for high-risk, locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) patients observed with Debio 1143 + CRT Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced the release of ...
plusNUCLEAI SECURED $6.5M SERIES-A INITIAL CLOSING LED BY DEBIOPHARM TO ADVANCE AI-POWERED PRECISION ONCOLOGY PLATFORM
Tel Aviv, Israel, Lausanne, Switzerland (ots) - - Nucleai, a computational biology company providing an AI-powered precision oncology platform for research and treatment decisions, secured $6.5M Series A initial closing. - Debiopharm's strategic corporate venture capital fund led the round joined by existing ...
plusWe+Care: EUR1.5 million to increase the quality at the end of life
plusThe International Osteoporosis Foundation (IOF)
New Capture the Fracture® partnership aims for 25% reduction in the incidence of hip and vertebral fractures due to osteoporosis by 2025
plusDebiopharm's Novel Microbiome Remodeling Program Licensed to Takeda for the Treatment of Gastrointestinal Disorders
Lausanne, Switzerland (ots) - Takeda will pursue the development of a novel preclinical narrow spectrum microbiome remodeling program, to treat diseases related to dysbiosis of the human gut microbiome Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today an exclusive license agreement ...
plusDebiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar® for Prostate Cancer
LAUSANNE, SWITZERLAND & WAYNE, PENNSYLVANIA (ots) - Debiopharm, a Swiss-based, biopharmaceutical company, and Verity Pharmaceuticals Inc., a US based specialty pharmaceutical company focused on therapeutic solutions for genitourinary (GU) diseases, today announced having entered into an exclusive agreement that ...
plusAcquisition of Debiopharm's investment portfolio company Kaiku Health broadens patient access to digital oncology intervention
Lausanne, Switzerland (ots) - - Debiopharm announces successful exit deal for Kaiku Health, a Finnish start-up specializing in digital solutions for improved patient outcomes and experience - Kaiku's acquisition by the Swedish company Elekta allows thousands of cancer treatment centers to gain access to the ...
plusWSSCC Names New Executive Director
plusForaCare Providing Critical Tools to Help Control COVID-19 Spread / Autonomous Temperature Measurement, Pulse Oximetry, TeleHealth System Help Medical Personnel, Businesses and Patients
plusEU Commission wants to postpone MDR implementation by one year / Swiss Medtech considers the postponement essential to ensure patient care
Bern (ots) - In view of the coronavirus pandemic, Swiss Medtech considers the EU Commission proposal to postpone the Medical Devices Regulation (MDR) date of application by one year to be imperative. The Association hopes that the Council and Parliament will also promptly agree with the recommendation. Ensuring the ...
plusAutonomous Thermometer System Launched to Assist in COVID-19 Pandemic
plus
Précédent567891011121314Suivant